Status:
COMPLETED
A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants
Lead Sponsor:
Pfizer
Conditions:
Healthy Participants
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to look at how healthy adults process Etrasimod when assessed by wearable sensors. Etrasimod is taken without food and assessments taken by site staff and then by particip...
Eligibility Criteria
Inclusion
- Healthy participants
- BMI 16 to 32 kg/m2
- body weight more than 50kg
Exclusion
- Ongoing or past history of significant medical conditions
- Eye disorders such as macular edema or uveitis
- Ongoing or recent infections
- Use of prescription or non prescription medications within 7 days of first dose
- Smoking or using nicotine products equivalent to more than 5 cigarettes per day
- History of severe allergic or anaphylactic reactions
Key Trial Info
Start Date :
December 20 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2024
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT06140290
Start Date
December 20 2023
End Date
March 1 2024
Last Update
March 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Clinical Research Unit - Brussels
Brussels, Bruxelles-capitale, Région de, Belgium, B-1070